检索结果-南通市图书馆

Hemophagocytic lymphohistiocytosis triggered by relapsing polychondritis:A case report

World Journal of Orthopedics 2024年第8期15卷 813-819页

作者： Mi-Ran Han Jeong-Hwan Hwang Seungah Cha So-Yeon Jeon Kyu Yun Jang namsu kim Chang-Hoon Lee Department of Internal Medicine Jeonbuk National University Medical SchoolJeonju 54907South Korea Department of Pathology Jeonbuk National University Medical SchoolJeonju 54907South Korea Department of Laboratory Medicine Jeonbuk National University Medical SchoolJeonju 54907South Korea

BACKGROUND Hemophagocytic lymphohistiocytosis(HLH)is a rare,life-threatening disorder caused by abnormal histiocytes and T cell *** adults,it is predominantly associated with infections,cancers,and autoimmune *** polychondritis(RP),another rare disease,is diagnosed based on symptoms without specific tests,featuring cartilage inflammation characterized by swelling,redness,and pain,rarely inducing *** SUMMARY A 74-year-old woman visited the emergency room with a fever of 38.6℃.Blood tests,cultures,and imaging were performed to evaluate *** showed increased fluorescent antinuclear antibody levels and mild cytopenia,with no other specific *** revealed lymph node enlargement was observed;however,biopsy results were *** re-evaluation of the physical exam,inflammatory signs suggestive of RP were observed in the ears and nose,prompting a tissue biopsy for ***,persistent fever accompanied by cytopenia prompted a bone marrow examination,revealing hemophagocytic *** finding no significant results in blood culture,viral markers,and tissue examination of enlarged lymph nodes,HLH was diagnosed by *** involved methylprednisolone followed by *** two months,bone marrow examination confirmed resolution of hemophagocytosis,with normalization of hyperferritinemia and *** Thorough physical examination enabled diagnosis and treatment of HLH trig gered by RP in patients presenting with fever of unknown origin.

关键词： Hemophagocytic lymphohistiocytosis Relapsing polychondritis Autoimmune disease Fever of unknown origin Steroid Case report

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Acute myelomonocytic leukemia and T-lymphoblastic lymphoma as simultaneous bilineage hematologic malignancy treated with decitabine:A case report

引用

World Journal of Clinical Cases 2023年第21期11卷 5129-5135页

作者： So-Yeon Jeon Na-Ri Lee Seungah Cha Ho-Young Yhim Jae-Yong Kwak Kyu Yun Jang namsu kim Yong Gon Cho Chang-Hoon Lee Department of Internal Medicine Jeonbuk National University Medical SchoolJeonju 54907South Korea Department of Pathology Jeonbuk National University Medical SchoolJeonju 54907South Korea Department of Laboratory Medicine Jeonbuk National University Medical SchoolJeonju 54907South Korea

BACKGROUND Simultaneous bilineage hematologic malignancies are rare;however,several cases of acute myeloid leukemia(AML)and T-lymphoblastic lymphoma(T-LBL)cooccurrence have been reported.A standard treatment for simultaneous AML and T-LBL has not yet been established,and its prognosis is very *** studies to develop standard treatments are required to increase patient survival *** SUMMARY A 69-year-old man complaining of pleuritic chest pain visited the emergency *** tomography revealed multiple enlarged lymph nodes(LNs)in the neck and groin and pulmonary thromboembolism with pulmonary ***,a peripheral blood smear performed due to leukocytosis revealed circulating *** myelomonocytic leukemia(AMML)was diagnosed after bone marrow examination,and T-LBL positivity for terminal deoxynucleotidyl transferase,cluster of differentiation(CD)34,and CD4 was confirmed by cervical LN *** and dexamethasone were administered because he could not receive intensive chemotherapy due to poor performance *** remission of AMML and T-LBL was achieved after 4 cycles of decitabine plus *** We report the therapeutic effect of decitabine,a hypomethylating agent(HMA),in patients with concurrent bilineage hematologic malignancies and suggest that further studies are required to evaluate the therapeutic effect of HMAs on both lymphoid and bilineage hematologic malignancies.

关键词： Simultaneous bilineage hematologic malignancies Acute myelomonocytic leukemia T-lymphoblastic lymphoma Decitabine Pulmonary thromboembolism Case report

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Attenuated FOLFIRINOX in the salvage treatment of gemcitabine-refractory advanced pancreatic cancer: a phase II study

引用

Cancer Communications 2018年第1期38卷 344-351页

作者： Jung Hoon kim Sang-Cheol Lee Sung Yong Oh Seo-Young Song namsu Lee Eun Mi Nam Soonil Lee In Gyu Hwang Hyo Rak Lee Kyu Taek Lee Sang-Byung Bae Han Jo kim Joung Soon Jang Do Hyoung Lim Hyun Woo Lee Seok Yun Kang Jung Hun Kang Department of Internal Medicine Institute of Health SciencesGyeongsang National University15 Jinju-daero 816beon-gilJinju 52727Republic of Korea Divsion of Hematology and Oncology Department of Internal MedicineSoonchunhyang University Hospital CheonanCheonan 31151Republic of Korea Department of Internal Medicine Dong-A University HospitalBusan 49201Republic of Korea Department of Internal Medicine Kangwon National University School of MedicineChuncheon 24289Republic of Korea Divsion of Hematology and Oncology Department of Internal MedicineSoonchunhyang University Hospital SeoulSeoul 04401Republic of Korea Department of Internal Medicine Ewha Womans UniversityCollege of MedicineSeoul 07985Republic of Korea Department of Internal Medicine Dankook University HospitalCheonan 31116Republic of Korea Department of Internal Medicine Chung-Ang UniversityCollege of MedicineSeoul 06973Republic of Korea Division of Hematology and Medical Oncology Department of Internal MedicineKorea Cancer HospitalSeoul 01812Republic of Korea Department of Hematology-Oncology Ajou University HospitalSuwon 16499Republic of Korea

Background:Combination therapy with oxaliplatin,irinotecan,fluorouracil,and leucovorin(FOLFIRINOX)chemotherapy drastically improves survival of advanced pancreatic cancer ***,the efficacy of FOLFIRINOX as a second-line treatment after gemcitabine failure has not been tested *** investigated the feasibility and safety of attenuated FOLFIRINOX in patients with gemcitabine-refractory advanced pancreatic ***:A multicenter phase II prospective open-label,single-arm study was conducted at 14 *** with histologically proven invasive ductal pancreatic adenocarcinoma,a measurable or evaluable lesion,Eastern Cooperative Oncology Group performance status 0 or 1,adequate organ function,and aged 19 years or older were *** FOLFIRINOX consisted of oxaliplatin 65 mg/m2,irinotecan 135 mg/m2,and leucovorin 400 mg/m2 injected intravenously on day 1 and 5-fluorouracil 2000 mg/m2 continuously infused intravenously over 46 h on days 1-2,repeated every 2 *** primary endpoint was progression-free survival from the initiation of *** endpoints were the objective response rate,disease control rate,overall survival,safety,and *** estimated overall survival and progression-free survival using the Kaplan-Meier ***:We enrolled 39 patients from 14 *** objective response rate was 10.3%,while the disease control rate was 64.1%.The 6-month and 1-year overall survival rates were 59.0%and 15.4%,*** progression-free survival and overall survival were 3.8 months(95%confidence interval[CI]1.5-6.0 months)and 8.5 months(95%CI 5.6-11.4 months),*** 3 or 4 adverse events were neutropenia(41.0%),nausea(10.3%),anorexia(10.3%),anemia(7.7%),mucositis(7.7%),pneumonia/pleural effusion(5.1%),and fatigue(5.1%).One treatment-related death attributable to septic shock ***:Attenuated FOLFIRINOX may be promising as a second-line therapy for gemcitabin

关键词： Attenuated FOLFIRINOX Second-line Pancreatic cancer Gemcitabine

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

减量FOLFIRINOX方案挽救性治疗吉西他滨抵抗的晚期胰腺癌:一项Ⅱ期研究

引用

癌症 2018年第8期37卷 327-335页

作者： Jung Hoon kim Sang-Cheol Lee Sung Yong Oh Seo-Young Song namsu Lee Eun Mi Nam Soonil Lee In Gyu Hwang Hyo Rak Lee Kyu Taek Lee Sang-Byung Bae Han Jo kim Joung Soon Jang Do Hyoung Lim Hyun Woo Lee Seok Yun Kang Jung Hun Kang Department of Internal Medicine Institute of Health SciencesGyeongsang National University Divsion of Hematology and Oncology Department of Internal MedicineSoonchunhyang University HospitalCheonan Department of Internal Medicine Dong-A University Hospital Department of Internal Medicine Kangwon National University School of Medicine Divsion of Hematology and Oncology Department of Internal MedicineSoonchunhyang University HospitalSeoul Department of Internal Medicine Ewha Womans UniversityCollege of Medicine Department of Internal Medicine Dankook University Hospital Department of Internal Medicine Chung-Ang UniversityCollege of Medicine Division of Hematology and Medical Oncology Department of Internal MedicineKorea Cancer Hospital Department of Hematology-Oncology Ajou University Hospital

背景与目的奥沙利铂、伊立替康、氟尿嘧啶和亚叶酸的联合化疗方案(FOLFIRINOX)极大提高了晚期胰腺癌患者的生存期。然而,FOLFIRINOX方案作为吉西他滨失败后二线治疗的疗效尚未进行前瞻性的检测。我们研究了减量FOLFIRINOX方案治疗吉西... 详细信息

背景与目的奥沙利铂、伊立替康、氟尿嘧啶和亚叶酸的联合化疗方案(FOLFIRINOX)极大提高了晚期胰腺癌患者的生存期。然而,FOLFIRINOX方案作为吉西他滨失败后二线治疗的疗效尚未进行前瞻性的检测。我们研究了减量FOLFIRINOX方案治疗吉西他滨抵抗的晚期胰腺癌患者的可行性和安全性。方法在14家医院进行了这一多中心II期前瞻、开放标签的单臂研究。经组织学确诊为胰腺浸润性导管腺癌、有可测量或可评价的病灶、东部肿瘤协作组体能状况评分0或1分、器官功能良好、年龄19岁或以上的患者符合入组条件。减量FOLFIRINOX方案的组成:奥沙利铂65 mg/m2、伊立替康135 mg/m2和亚叶酸400 mg/m2,第1天静脉注射;5?氟尿嘧啶2000 mg/m2,第1–2天持续静脉输注46 h;每2周重复。主要终点为FOLIFLIOX治疗起始后的无进展生存期。次要终点为客观缓解率、疾病控制率、总生存期、安全性和耐受性。采用Kaplan?Meier法评估了总生存期和无进展生存期。结果我们招募了来自14个中心的39例患者。客观缓解率为10.3%,疾病控制率为64.1%。6个月和1年总生存率分别为59.0%和15.4%。中位无进展生存期和总生存期分别为3.8个月[95%置信区间(confidence interval,CI)=1.5–6.0个月]和8.5个月(95%CI=5.6–11.4个月)。3或4级不良事件为中性粒细胞减少(41%)、恶心(10.3%)、食欲减退(10.3%)、贫血(7.7%)、黏膜炎(7.7%)、肺炎/胸膜融合(5.1%)和乏力(5.1%)。发生1例由感染性休克引起的治疗相关死亡。结论减量FOLFIRINOX方案有望作为二线方案治疗吉西他滨抵抗的胰腺癌。

关键词：减量FOLFIRINOX方案二线治疗胰腺癌吉西他滨

来源：

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：